{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T04:48:18Z","timestamp":1750308498842,"version":"3.41.0"},"publisher-location":"New York, NY, USA","reference-count":29,"publisher":"ACM","license":[{"start":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:00:00Z","timestamp":1736985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.acm.org\/publications\/policies\/copyright_policy#Background"}],"funder":[{"name":"2020 Suzhou Science and Technology Development Programme Fund","award":["SYSD2020169"],"award-info":[{"award-number":["SYSD2020169"]}]},{"name":"2024 Suzhou Science and Technology Development Programme Fund","award":["SYWD2024266"],"award-info":[{"award-number":["SYWD2024266"]}]},{"name":"2024 Jiangsu Provincial Hospital Association Hospital Pharmacy Management Research Special Project Fund","award":["JSYGY-3-2024-YS44"],"award-info":[{"award-number":["JSYGY-3-2024-YS44"]}]},{"name":"2024 Jiangsu Provincial Pharmaceutical Association - Aosaikang\u00a0Pharmaceutical\u00a0Fund","award":["A202431"],"award-info":[{"award-number":["A202431"]}]}],"content-domain":{"domain":["dl.acm.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1,16]]},"DOI":"10.1145\/3722150.3722155","type":"proceedings-article","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T10:37:39Z","timestamp":1747132659000},"page":"28-34","update-policy":"https:\/\/doi.org\/10.1145\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacoeconomic analysis of entecavir based on Markov model"],"prefix":"10.1145","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-0948-6698","authenticated-orcid":false,"given":"Hui","family":"Tang","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Changshu No.1 People's Hospital, Changshu Hospital Affiliated to Suzhou University, Su zhou, Jiangsu, China"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3328-3875","authenticated-orcid":false,"given":"Xia","family":"Tian","sequence":"additional","affiliation":[{"name":"Department of Rational Medication, Changshu No.1 People's Hospital, Changshu Hospital Affiliated to Suzhou University, Su zhou, Jiangsu, China"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4688-9009","authenticated-orcid":false,"given":"Kaijian","family":"Xia","sequence":"additional","affiliation":[{"name":"Department of Scientific and Research, Changshu No.1 People's Hospital, Changshu Hospital Affiliated to Suzhou University, Su zhou, Jiangsu, China"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6263-7507","authenticated-orcid":false,"given":"Ping","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Scientific and Research, Changshu No.1 People's Hospital, Changshu Hospital Affiliated to Suzhou University, Su zhou, Jiangsu, China"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6491-4555","authenticated-orcid":false,"given":"Xiaoming","family":"Qian","sequence":"additional","affiliation":[{"name":"Medical Security Bureau of Changshu City, Su zhou, Jiangsu, China"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6722-9520","authenticated-orcid":false,"given":"Tianxiang","family":"Shen","sequence":"additional","affiliation":[{"name":"Science and Technology Bureau of Changshu City, Su zhou, Jiangsu, China"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6711-8601","authenticated-orcid":false,"given":"Wei","family":"Huang","sequence":"additional","affiliation":[{"name":"Emergency Department, Changshu No.2 People's Hospital, Su zhou, Jiangsu, China"}]}],"member":"320","published-online":{"date-parts":[[2025,5,13]]},"reference":[{"key":"e_1_3_3_1_2_2","first-page":"2648","volume":"201","author":"Liver Disease Society of Chinese Medical Association, Infectious Disease Society of Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2019).","unstructured":"Liver Disease Society of Chinese Medical Association, Infectious Disease Society of Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2019). J Clin Hepatol. 2019;35(12):2648-2669.","journal-title":"J Clin Hepatol."},{"key":"e_1_3_3_1_3_2","volume-title":"China guidelines for pharmacoeconomic evaluations","author":"Liu GG.","year":"2020","unstructured":"Liu GG. China guidelines for pharmacoeconomic evaluations. Beijing: China Market Press; 2020. p. 177."},{"key":"e_1_3_3_1_4_2","volume-title":"World health statistics 2018: monitoring health for the SDGs [Internet]","author":"World Health Organization","year":"2018","unstructured":"World Health Organization. World health statistics 2018: monitoring health for the SDGs [Internet]. Geneva: WHO; 2018 [cited 2024 Jun 18]. Available from: https:\/\/www.who.int\/gho\/publications\/world_health_statistics\/2018\/en\/."},{"key":"e_1_3_3_1_5_2","unstructured":"The overall situation of liver transplantation in China from 1980 to 2010. Chinese Journal of Transplantation(Electronic Edition). 2011;5(04):267-269."},{"key":"e_1_3_3_1_6_2","first-page":"1053","volume":"201","author":"Ye XG","unstructured":"Ye XG, Ouyang RJ. Cost-effectiveness of telbivudine-based optimization and entecavir monotherapy in patients with HBeAg-positive chronic hepatitis B. The Journal of Practical Medicine. 2015;31(07):1053-1057.","journal-title":"Practical Medicine."},{"key":"e_1_3_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23327"},{"key":"e_1_3_3_1_8_2","doi-asserted-by":"publisher","unstructured":"Lampertico P Agarwal K Berg T Buti M Janssen HLA Papatheodoridis G et al. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. Journal of Hepatology. 2017 Aug;67(2):370-398. doi: 10.1016\/j.jhep.2017.03.021. PMID: 28427875.","DOI":"10.1016\/j.jhep.2017.03.021"},{"key":"e_1_3_3_1_9_2","first-page":"592","volume":"2010","author":"Wu B","unstructured":"Wu B, Li T, Chen H, Shen J. Cost-Effectiveness of Nucleoside Analog Therapy for Hepatitis B in China: A Markov Analysis. Value in Health. 2010 Jul;13(5):592\u2013600.","journal-title":"Health."},{"key":"e_1_3_3_1_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2006.00769.x"},{"key":"e_1_3_3_1_11_2","first-page":"437","volume":"200","author":"Huang H","unstructured":"Huang H, Zhu CW, Yu XF, Wang GS, Qang JY. The development of cirrhosis in Chinese patients with chronic hepatitis B. Chinese Hepatology. 2007;6(12):437-440.","journal-title":"Chinese Hepatology."},{"key":"e_1_3_3_1_12_2","first-page":"46","volume":"200","author":"Wu GC","unstructured":"Wu GC, Zhou WP, Zhao YR, Guo SH, Wang ZY, Zou SB, et al. Study of chronic hepatitis B complicated with liver cirrhosis. Chinese Journal of Hepatology. 2002;1(01):46-48.","journal-title":"Chinese Journal of Hepatology."},{"key":"e_1_3_3_1_13_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1746.2003.03187.x"},{"key":"e_1_3_3_1_14_2","doi-asserted-by":"publisher","unstructured":"Chen CJ Yang HI Iloeje UH. Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Hepatology. 2009 Apr 27;49(S5):S72-84.doi: 10.1002\/hep.22884. PMID: 19399801.","DOI":"10.1002\/hep.22884"},{"key":"e_1_3_3_1_15_2","unstructured":"National Bureau of Statistics of China. Tabulation on the 2010 Population Census of the People's Republic of China [Internet]. Available from: http:\/\/www.stats.gov.cn\/tjsj\/pcsj\/rkpc\/6rp\/indexch.htm."},{"key":"e_1_3_3_1_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-007-5001-0"},{"key":"e_1_3_3_1_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-200205000-00018"},{"key":"e_1_3_3_1_18_2","first-page":"2157","volume":"2012","author":"Wang SB","unstructured":"Wang SB, Wang JH, Chen J, Giri RK, Chen MH. Natural history of liver cirrhosis in south China based on a large cohort study in one center: a follow-up study for up to 5 years in 920 patients. Chinese Medical Journal. 2012 Jun;125(12):2157-62.","journal-title":"Chinese Medical Journal."},{"key":"e_1_3_3_1_19_2","unstructured":"Xie W Yan J Zhao H. Expert Committee on Chronic Hepatitis B Combined with Antiviral Therapy. Expert consensus on chronic hepatitis B combined with antiviral therapy. Chinese Journal of Liver Diseases(Electronic Edition). 2011;3(02):38-45."},{"key":"e_1_3_3_1_20_2","doi-asserted-by":"publisher","unstructured":"Dienstag JL. Benefits and risks of nucleoside analog therapy for hepatitis B. Hepatology. 2009 Apr 27;49(S5):S112-21.doi: 10.1002\/hep.22920.","DOI":"10.1002\/hep.22920"},{"key":"e_1_3_3_1_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2008.10.001"},{"key":"e_1_3_3_1_22_2","doi-asserted-by":"publisher","DOI":"10.11569\/wcjd.v22.i14.2028"},{"key":"e_1_3_3_1_23_2","first-page":"434","volume":"202","author":"Huang YQ","unstructured":"Huang YQ, Zhang HY, Li SS, Li MQ, Jia QD, Liang HX. Evaluating the efficacy and safety of centrally collected Entecavir in patients with chronic hepatitis B. Chinese Journal of Gastroenterology and Hepatology. 2022;31(04):434-437.","journal-title":"Hepatology."},{"key":"e_1_3_3_1_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2007.00297.x"},{"key":"e_1_3_3_1_25_2","doi-asserted-by":"publisher","DOI":"10.14218\/JCTH.2022.00167"},{"key":"e_1_3_3_1_26_2","doi-asserted-by":"publisher","unstructured":"Wen X Yin S Cui L Mao L Lin Z Yaermaimaiti Z et al. The Effects of the National Centralized Drug Purchasing Pilot Program on Nucleos(t)ide Analogs in Shenzhen City: An Interrupted Time Series Analysis. Frontiers in Public Health. 2021 Oct 25;9:718013. doi: 10.3389\/fpubh.2021.718013.","DOI":"10.3389\/fpubh.2021.718013"},{"key":"e_1_3_3_1_27_2","volume-title":"\u201c4+7","author":"Chen WX","year":"2021","unstructured":"Chen WX, Xia F, Chen ZB, Ou F. Analysis of the impact of \u201c4+7\u201d on the hospitalized patients' cost in Guangzhou public hospitals. China Journal of Pharmaceutical Economics. 2021;16(07):13-17+23."},{"key":"e_1_3_3_1_28_2","doi-asserted-by":"publisher","unstructured":"Hou JL Zhao W Lee C Hann HW Peng CY Tanwandee T et al. Outcomes of long-term treatment of chronic HBV infection with entecavir or other agents from a randomized trial in 24 countries. Clin Gastroenterol Hepatol. 2020 Feb;18(2):457-467.e21. doi: 10.1016\/j.cgh.2019.07.010.","DOI":"10.1016\/j.cgh.2019.07.010"},{"key":"e_1_3_3_1_29_2","unstructured":"Xu JH Yu YY Si CW Zeng Z Li J Mao Q et al. A randomized double-blind double-dummy controlled multicenter study of entecavir maleate versus entecavir for treatment of chronic hepatitis B: results at week 96. Chinese Journal of Infectious Diseases. 2014;32(10):594-600."},{"key":"e_1_3_3_1_30_2","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.00000000000004"}],"event":{"name":"CCEAI 2025: 2025 9th International Conference on Control Engineering and Artificial Intelligence","acronym":"CCEAI 2025","location":"Ho Chi Minh City Vietnam"},"container-title":["Proceedings of the 2025 9th International Conference on Control Engineering and Artificial Intelligence"],"original-title":[],"link":[{"URL":"https:\/\/dl.acm.org\/doi\/10.1145\/3722150.3722155","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dl.acm.org\/doi\/pdf\/10.1145\/3722150.3722155","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T18:43:50Z","timestamp":1750272230000},"score":1,"resource":{"primary":{"URL":"https:\/\/dl.acm.org\/doi\/10.1145\/3722150.3722155"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,16]]},"references-count":29,"alternative-id":["10.1145\/3722150.3722155","10.1145\/3722150"],"URL":"https:\/\/doi.org\/10.1145\/3722150.3722155","relation":{},"subject":[],"published":{"date-parts":[[2025,1,16]]},"assertion":[{"value":"2025-05-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}